ognize its importance in diagnosing and treating illness. However, most clients are less trusting because they understand little about science and medicine. They are quick to ignore or disregard complex scientific data in favor of anecdotal evidence and other factors easier to comprehend, but less reliable.
The silicone breast implant issue graphically illustrates problems that arise when a disconnect exists between scientific evidence and public perception. A medical device which once offered women restoration of body wholeness and improvement of body image is now the subject of countless disease claims, rampant litigation, and emotionally charged publicity. Trial attorneys, often motivated by millions of dollars in contingency fees, have promoted anecdotal evidence and unsubstantiated "junk science" to bolster baseless claims that silicone breast implants are dangerous. This has occurred even though the overwhelming weight of scientific evidence demonstrates no association between silicone breast implants and disease. As a result, some women continue to believe their implants cause a variety of health problems which range from headaches and nausea to lupus and rheumatoid arthritis.
While there is no question some women with breast implants are seriously ill, the weight of the scientific evidence should reassure them their silicone breast implants are not the cause of their illnesses. These individuals deserve to be properly diagnosed so they can receive appropriate health care treatment.
Sandy Butterfield, a registered nurse and independent health care consultant with the Center for Civil Justice Studies, noted in a recent editorial, The real victims in this new American tragedy are the thousands of women who, persuaded, or perhaps simply unnerved by trial lawyers' propaganda, may attribute genuine symptoms to a false cause-their breast implants-and fail to seek proper treatment for very real diseases. In some cases, the failure to have an actual disease treated properly may well be life threatening (Butterfield, S. 'The implant scare: Trial lawyers play on women's fears, line their own pockets with millions." The Tulsa World, July 31, 1996) .
HISTORICAL BACKGROUND
Silicone breast implants were developed in the early 1960s by doctors at Baylor College of Medicine, Houston, Texas. The device entered the market in 1964. The first recipient still has her original implants. At that time, medical devices were not regulated by the United States Food and Drug Administration (FDA). In fact, it was not until 1976, 12 years later, that the FDA required manufacturers of medical devices to submit evidence about the safety and effectiveness of certain medical devices (Angell, 1996a) .
This does not mean that studies were not performed until the FDA mandate. The change in the rule meant only that the FDA wanted to see the research findings. Implant manufacturers had previously conducted or funded hundreds of toxicological and industrial hygiene studies related to the materials used in implants, along with the implants themselves. As a result, the FDA allowed manufacturers to keep the devices on the market without providing supportive data to the agency.
In the early 1980s, three case reports appeared in the medical literature suggesting a possible connection between breast implants and autoimmune diseases, such as lupus and rheumatoid arthritis (Angell, 1996b) . A widely publicized lawsuit against Dow Coming in 1991 resulted in a verdict against the company for millions of dollars in punitive damages. In addition, a network television program drew national attention to the issue.
In light of the growing public concern, then FDA Commissioner David Kessler convened an advisory panel. The panel members expressed frustration that the available reports were based on anecdotes rather than epidemiologic or toxicologic evidence (Connell, 1995) .
Until more research could be completed, the FDA (in 1992) imposed a limited moratorium on silicone breast implants. In issuing the moratorium, the FDA did not declare implants unsafe. Rather, the FDA stated more studies were needed that showed implants were safe (FDA, 1997a) . While reconstructive surgery for individuals with breast cancer is one of the exceptions under the moratorium, to receive silicone breast implants women must agree to participate in a clinical trial. That means they must live near, or travel to, a participating research center over an extended period of time and at their own expense.
Confusion about FDA restrictions, along with extensive media attention to the controversy, spread needless fear among the estimated one million women with silicone breast implants. Some women had their implants removed surgically. Tragically, at least one woman who could not afford the operation tried to carve out her implants with a razor blade (Angell, 1996a) .
Commenting on the FDA's investigation and moratorium, Connell (1995) , former chair of the FDA advisory panel and professor emeritus of obstetrics and gynecology, Emory University, said:
...[tjhe fact remains that there is no finding of a link between implants and disease. ... All of this could have, and should have, been avoided.
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Although no solid scientific evidence supported the connection between silicone and disease, extensive media coverage and the FDA restrictions opened the floodgates to thousands of lawsuits against implant manufacturers. Trial attorneys across the United States actively recruited women with implants, placing newspaper ads, holding informational meetings, and steering them to "selected" physicians for implant related diagnoses.
In the first 2 years of the moratorium, 20,000 lawsuits were filed against implant manufacturer Dow Coming. Ultimately, the breast implant case became the largest mass tort litigation in history. In 1995, Dow Coming sought protection under federal bankruptcy laws.
In February 1998, Dow Coming proposed a $4.4 billion dollar plan of reorganization, its third proposal in as many years, in an attempt to emerge from bankruptcy protection. Of the total, $3 billion was targeted primarily for resolving product liability claims, including breast implant claims. In April, Judge Arthur Spector, overseer of Dow Coming's bankruptcy reorganization, held hearings to review the proposal. At his urging Dow Coming, the Tort Claimants Committee, which represents the plaintiffs, and Duke University Law School Professor Francis McGovern, a special mediator, have been meeting for several months to negotiate a final, mutually acceptable resolution to the litigation. All of this has occurred despite the fact that no single, peer reviewed scientific study has found an association between silicone breast implants and systemic disease.
SCIENTIFIC EVIDENCE
While this legal speed train was hurtling down the track, scientists at leading health care research institutions were completing large scale epidemiologic studies of women with breast implants to determine whether there was an association or possible cause. These studies compared women with breast implants to women without breast implants to determine if the women with implants had higher rates of disease than women without implants. The new studies added to the existing toxicologic, hematologic, clinical, and other studies that supported the safety of breast implants.
Since the moratorium was issued, more than 20 epidemiologic studies have been conducted by respected health care research institutions in the United States and from around the world, including Harvard, Johns Hopkins, and the Mayo Clinic. The overwhelming weight of the scientific evidence demonstrates there is no association between silicone breast implants and systemic disease. In one large study in the United .States, researchers raised the possibility of a small risk, but stated the risk was so small it could not be reliably distinguished from no risk at all (Brigham and Women's Hospital, 1996) .
It must be noted these studies do not pertain to local complications, which can occur with any surgery or implanted medical device. These include local complications from the surgery itself, such as infection or hemorrhage, as well as from the implant, such as hardening, leakage, or rupture. These complications have been well known by the medical community for decades and were publicized in medical literature , yet have been confused with systemic diseases. However, as Angell (1996a) noted: "...[T]hese local complications, unpleasant as they were, were not the basis for most of the alarm about breast implants, nor were they the focus of the multimillion-dollar lawsuits." Instead, the lawsuits and most of the studies have focused on the relationship between implants and autoimmune diseases such as lupus, rheumatoid arthritis, and scleroderma. Autoimmune diseases remain among the most NOVEMBER 1998, VOL. 46, NO. 11 poorly understood and poorly recognized of any category of illnesses. Symptoms vary widely, but the underlying problem is similar. The body's immune system becomes misdirected, attacking the very organs it was designed to protect. About three quarters of all cases occur in women. Importantly, no known causes or cure exist, although hormones and genetics are believed to playa role (U.S. Public Health Service).
Reviewing the findings from several of the epidemiology studies demonstrated the strength of the scientific evidence finding no association between silicone breast implants and systemic disease. One of the first large scale epidemiologic studies (Gabriel, 1994) compared medical records of 749 women who had received breast implants with those of about 1,500 women who had not received implants. The final report stated: "We found no association between breast implants and the connective tissue diseases and other disorders that were studied (Gabriel, 1994) " (see Tables 1 and 2) .
The largest of the retrospective cohort studies was funded by the National Institutes of Health. Drawing on data compiled for the ongoing Harvard Nurses' Health 540 Study, it examined the incidence of connective tissue disease and 41 signs, symptoms, or laboratory findings of connective tissue disease among 1,200 registered nurses with implants compared to a control group of 86,000 women without implants. The authors concluded: "In a large cohort study, we did not find an association between silicone breast implants and connective tissue diseases, defined according to a variety of standardized criteria, or signs and symptoms of these diseases" (Sanchez-Guerrero, 1995) (see Table 3 ). Hennekens (1996) conducted the largest study to date. It suggested a small increased risk of an association between breast implants and connective tissue disease, The study assessed self reported data by female health professionals-more than 10,800 women with implants and nearly 385,000 without-on six connective tissue diseases. The authors found no increased risk for five of the six categories analyzed. The sixth category, "other NOVEMBER 1998, VOL. 46, NO. 11
connective tissue disease including mixed," found an increased risk so small the authors stated: "... It will be difficult to distinguish reliably between a small hazard and no hazard (Hennekens, 1996) " (see Table 4 ). According to Hennekens (Brigham and Women's Hospital, 1996) , Considering all available evidence, women with breast implants should be reassured that there is no large risk of connective tissue disease. These study results are consistent with the findings of two other large cohort studies on breast implants. Friis (1997) conducted a study in which 2,570 women who received breast implants were compared with some 11,000 women who had breast surgery but no implants. The findings showed no increased rate of connective tissue disease among women with silicone breast implants. The researchers concluded , "We found no significant excess of definite CTDs (connective tissue diseases) among women with breast implants" (see Table 5 ).
Additionally, the American Medical Association (1993), the American College of Rheumatology (1996), the American Academy of Neurology (Ferguson, 1997) , and the U.K. Medical Devices Agency (1997) have all reviewed the scientific evidence and found no relationship between silicone breast implants and disease.
Even former FDA Commissioner Kessler, on a program (PBS "Frontline," 1996) about the silicone implant controversy, concurred , "...There is no evidence that supports the association between silicone and either typical or atypical connective tissue diseases. The scientific evidence just is not there to support that association."
Unfortunately, 4 years of news stories reporting the alleged hazards of implants as if they were fact had already framed public perception . Isolated reports were 542 accepted as absolute truths by the courts and the public. Scientific facts published in prestigious medical journals since 1994 largely have failed to attract the attention of the general public.
IMPACT FOR CLIENTS WITH BREAST CANCER
The FDA moratorium has engendered a climate in which women are fearful of breast implants. Far from protecting the health of women, the moratorium has needlessly terrified women with implants, as well as women considering implants. Unfortunately this may include women with breast cancer. With limited options for reconstructive surgery, women may be more hesitant to get check ups as often as is necessary to detect breast cancer in the early stages when it is still treatable. Many breast cancer survivors believe that available reconstruction options offered them the chance to heal mentally as well as physically and to move forward with their lives. In September 1996, health care and consumer . groups, including the American Cancer Society, the National Alliance of Breast Cancer Organizations, American Society of Clinical Oncology, and Y-ME National Breast Cancer Organization filed a petition with the FDA to ease its restrictions on silicone breast implants (American Cancer Society, 1996) . CanDo, a group opposed to silicone breast implants, also filed a petition, asking for a recall of the devices. In response to these competing petitions, the FDA z 
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recently reconsidered its moratorium on silicone breast implants and decided not to change its policy at that time.
It is important to note that the agency also declined a request filed by CanDo to recall the devices. In its decision to maintain the moratorium, the FDA (1997b) stated it is in the "best interest of many breast cancer patients to have access to the devices." With this in mind, the FDA is working to expand access for these women within the current guidelines.
HEALTH CARE IMPACT
The reach of the silicone story extends much further and touches all Americans, even future generations. In a broader sense, the silicone breast implant litigation and other product liability lawsuits against drug and medical device manufacturers have had profound effects on Americans' health care choices.
As companies pour more resources into mounting legal defenses for safe and reliable products, fewer dollars are available to fund new research. In addition, fear of lawsuits is having a chilling effect on research and the development of a whole range of life saving and life enhancing pharmaceuticals, vaccines, and medical devices. For example, a major biotech firm declined to develop an AIDS vaccine because of liability concerns (Vincent, 1993) . Fear of legal retribution forced one leading firm to withdraw from clinical trials on a new vaccine at the National Institutes of Health that could have prevented the transmission of HIV from infected mothers to their unborn children (Bennett-Warner, C. "Why the legal system is bad medicine." The San Diego Tribune, May 7, 1995) .
Manufacturers of raw materials used to make medical devices have also reacted to the legal climate. In response to the growing threat of litigation, at least 14 major suppliers of raw materials have halted sales in the past several years to United States manufacturers of medical devices (Kahanovitz, 1997) . In fact, a recent survey found that 75% of responding companies are not willing to supply to implant manufacturers because of liability risks (Aronoff Associates, 1997) . Life saving and life enhancing devices such as pacemakers, brain shunts, heart valves, and replacement joints eventually may not be available (Petition to Congress, 1997). Greenberger (1995) , executive director of the Society for the Advancement of Women's Health Research, stated:
For those of us in good health, the loss of these substances seems inconsequential. Yet for those suffering from osteoporosis, heart disease, rheumatoid arthritis and other diseases, access to a full range of medical devices is crucial.
Runaway litigation may cause shortages, escalating prices, or even the complete disappearance of implanted medical devices as raw material suppliers stop selling to medical markets and device makers move overseas where baseless lawsuits are less of a threat. Biomaterials industry experts say the lack of raw materials for medical devices may soon reach crisis proportions, with more 544 than 7.5 million American clients affected annually (Health Industry Manufacturers Association, 1996) . Kent (1997) , director of the Washington Cardiology Center, summed up the problem while testifying before Congress:
Without the availability of the raw materials for medical devices, children born with hydrocephalus ... will die or have debilitating mental retardation. Patients with coronary heart disease will die or be incapacitated by crippling angina. Elderly patients who break their hips will remain in the hospital for months instead of days, and our elderly patients will go blind instead of having their eyesight restored .... We will tum the practice of medicine back to the 1930s.
Perhaps nowhere is the negative impact of the United States legal system on health care more visible than in the area of reproductive health. Today,American women have fewer contraceptive choices than women in Europe due to the explosion of litigation costs in the United States. According to a recent report by a branch of the National Academy of Sciences (Institute of Medicine, 1996) , fear of product liability lawsuits has stopped nearly all in house research on new,better, and safer contraceptives.The number of large United States pharmaceutical companies involved in research and development for contraceptives dropped from nine to one by the rnid-1980s (Bryant, 1995) .
The latest contraceptive targeted by tort attorneys is Norplant, which consists of six matchstick sized capsules surgically placed in a woman's upper arm. Some lawsuits allege the implants are damaging because they are sheathed in silicone (Independent Women's Forum, 1997) . Connell (1995) told Congress,
We are currently witnessing massive litigation being mounted against an excellent contraceptive product. ... Plaintiffs' attorneys once again claim that it causes autoimmune disease in the total absence of scientific evidence.
Healy, former director of the National Institutes of Health, wrote in a recent editorial, Women live longer and suffer from chronic diseases (such as osteoporosis) to a greater extent than men. More than men, we will rely on new drugs and therapies to combat these debilitating diseases. Unfortunately, unpredictable and excessive product liability costs are forcing drug and medical device companies to withdraw needed products, or even to decline to develop them....We don't need women's advocates who protect a liability system that limits our health care choices by turning businesses away from women's health.... But just as women's health has finally been upgraded to first class, we cannot abide a liability system that holds women back in the dark ages of medicine (Healy, B. "Tort tax on women's health. The Washington Post, April 28, 1995).
The same massive legal assaults that affect the development of new medical devices also threaten to undermine some of the most important independent research institutions. As demonstrated with alarming clarity in breast implant litigation, harassment of researchers has become a commonplace tactic of plaintiffs' lawyers.
In the courtroom, scientists at esteemed institutions such as Harvard University and The Mayo Clinic are being subpoenaed and personally attacked. Plaintiffs' lawyers paint these scientists as either incompetent or corrupt because their studies were even partially sponsored by industry, even though time tested policies exist to insulate research from outside influence (Angell, 1996a) . Connell (1995) remarked on the impact of these attacks, ...As a scientific community, [we] have been appalled at the way researchers and their institutions have been attacked. I can't think of anything in my lifetime that has been as destructive to women and their potential for good health care.
As a result, some institutions have imposed tighter restrictions on their researchers to defend their work publicly and have raised concerns that trial lawyers' subpoenas would force disclosure of private data, such as client medical records in open court, possibly discouraging people from participating in future studies.
Finally, the breast implant saga also has dealt a significant blow to the concept of health care provider/client choice. One of eight OB/GYN physicians has left the specialty (American College of Obstetricians and Gynecologists, 1992) . Health care providers also may be limited in what devices they can offer women, regardless of the fact that research shows the device to be safe. Women clients, they must assume, are not capable of evaluating their options in consultation with their health care providers.
The effects of the silicone breast implant case make clear that without effective civil justice reform, the current legal system threatens to undermine scientific progress on health issues vital to all Americans. While every citizen's legal right to sue a company acting irresponsibly must be preserved, reforms are needed to prevent groundless lawsuits from clogging the legal system and imposing huge costs to society. Swift action at the federal and state levels to restrict punitive damages, joint and several liability in product cases, and contingency fees-incentives that fuel mass litigation-is urgently needed. Also, responsible judges must be appointed or elected to eliminate the use of scientifically invalid theories and create scientific panels to help juries sort out valid science from 'junk science."
IMPLICATIONS FOR NURSES IN THE WORKPLACE
More than one million women have had silicone breast implants and are justifiably frightened by the confusion surrounding these complex issues. Some women with silicone breast implants have subsequently become ill. Because the weight of scientific evidence does not support an association between breast implants and disease, the concern exists these women are not receiving proper diagnosis and treatment for their legitimate illnesses. NOVEMBER 1998, VOL. 46, NO. 11 Nancy Dickey, president of the American Medical Association, has urged all health care professionals to play an active role in clearing up the rampant misinformation about the silicone breast implant issue:
The federal government is not solely responsible for clearing up this mass confusion and ending the heartbreak caused by plaintiff lawyers and their hired doctors. Central to the patient-physician relationship is the obligation of doctors to always do what is best for their patients. If we don't stand up for scientific and professional integrity, we risk losing not only our patients' trust, but society's trust as well (Dickey, N. "Scientific integrity of medical profession harmed by doctors' pre-scripted diagnoses to trial lawyers." The Chicago Tribune, October 20, 1996) .
Nurses in the workplace are on the front line with clients and are responsible for addressing concerns and fears that a particular exposure is causing an illness or symptom, whether that exposure is silicone, solvents, particulates, or electromagnetic fields. While showing empathy for client fears, it is vital to serve as the voice of science by interpreting complex toxicologic and epidemiologic research. Is their exposure making them sick? This is the question that nurses must answer. As health care professionals, nurses in the workplace have a responsibility to defend science and dispel misinformation about silicone breast implants and other health care devices and procedures.
Overinterpreting the implications of individual case studies must be avoided. If a woman gets breast implants and later develops multiple sclerosis (MS), does that mean her breast implants caused the MS? Only epidemiology, the controlled study of large populations with and without an exposure, can make that determination with a reasonable degree of scientific certainty.
At the same time, the concerns and fears of clients cannot be dismissed. Much is still to be learned about exposure based health effects. By treating clients callously and dismissively, nurses risk losing credibility.
The silicone breast implant story is a cautionary tale about the effects of misinformation, sensationalism, and fear of the diagnosis and treatment of complex illnesses. Unless society learns from this tale, it stands to be repeated. The continued health of current and future clients depends on respect and understanding of scientific research.
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A medical device that once offered women restoration of body wholeness and improved body image is now the subject of multiple disease claims, major litigation, and emotionally charged publicity. As a result, thousands of women believe their implants cause a variety of health problems.
More than 20 epidemiologic studies have been conducted by respected health care institutions worldwide. The overwhelming weight of scientific evidence demonstrates there is no association between silicone breast implants and systemic disease.
Fear of lawsuits has a chilling effect on research and development of a whole range of life saving and life enhancing pharmaceuticals, vaccines, and medical devices leading to shortages, escalating prices, or even the disappearance of many implanted devices.
As health care providers, nurses must interpret complex toxicologic and epidemiologic research.
